Back to resultsUse of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
Primary Purpose
Liver Failure
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
ELAD®
Sponsored by
About this trial
This is an expanded access trial for Liver Failure focused on measuring Expanded access to ELAD® in patients with liver failure
Eligibility Criteria
Inclusion Criteria:
- Weight ≥15 kg;
- Age ≥10 and ≤70 years;
- MELD score of ≥24;
- Documented liver failure;
- Subject or designated representative must be willing to sign an Informed Consent Form specific to this study and comply with study requirements.
Exclusion Criteria:
Cerebral Perfusion Pressure (CPP) as measured by an intracranial pressure (ICP) monitor.:
- Patients ≥ 18 yrs of age with Cerebral Perfusion Pressures ≤40 mm Hg for one hour or longer.
- Patients ≤18 yrs with CPP ≤35 mm Hg for one hour or longer.
- Concomitant disease including chronic congestive heart failure, vascular disease, emphysema, AIDS, cancer, acute fatty-liver disease, hepatitis due to herpes virus, Wilson's disease, or Budd-Chiari syndrome;
- Portal hypertension;
- Liver dysfunction due to trauma;
- Hemorrhage or irreversible brain death;
- Platelet count <50,000/mm3 or reducing to <80,000/mm3 over a 72 hour period;
- Mean Arterial Pressures (MAP) ≤50 mm Hg for one hour or longer as measured by an indwelling arterial line, OR; patients ≤18 years old and whose MAP is ≤40 mm Hg for one hour or longer;
- Vasopressor support exceeding 1.0 µg/kg/min of an alpha-adrenergic agent for one hour or longer;
- Clinical or radiographic evidence of stroke or intracerebral bleeding;
- Seizures uncontrolled by medication;
- Acute myocardial infarction based on clinical and/or electrocardiographic evidence;
- Lung disease defined by a PaO2 ≤ 60mm Hg or an FiO2 ≥0.6;
- Pregnancy as determined by βhCG results;
- ≤2 weeks postpartum;
- Eligible for an open ELAD clinical trial
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00832273
First Posted
January 29, 2009
Last Updated
September 9, 2013
Sponsor
Vital Therapies, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00832273
Brief Title
Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
Official Title
Use of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Liver Failure: Uncontrolled Treatment Protocol to Provide Expanded Access With Cost Recovery
Study Type
Expanded Access
2. Study Status
Record Verification Date
September 2013
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vital Therapies, Inc.
4. Oversight
5. Study Description
Brief Summary
VTI had established other clinical protocols to study the effects of ELAD® plus standard therapy compared with standard therapy alone in patients with acute on chronic (AOCH) (VTI-201, VTI-206) and fulminant hepatic failure (FHF) (VTI-202) and acute alcoholic hepatitis (AAH). However, liver failure (LF) patients who do not qualify for other protocols may benefit from ELAD use. In order to accommodate physician requests for the use of ELAD in LF patients who do not qualify for open Protocols, without the need to resort to individual Emergency Use INDs for each case, VTI has developed a Treatment Protocol with Cost Recovery to provide for expanded access to ELAD for those with LF. This uncontrolled Treatment Protocol has been designed to provide expanded access to ELAD in subjects with LF while assuring that sufficient data are collected to adequately monitor ELAD safety when used in this setting at multiple centers in the United States.
Detailed Description
ELAD® therapy is designed to provide continuous liver support to a subject with compromised liver function, allowing time for the subject's native liver to regenerate to a healthy state, or to stabilize the subject until a suitable donor organ can be found for transplantation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Failure
Keywords
Expanded access to ELAD® in patients with liver failure
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
ELAD®
Intervention Description
liver assist system
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
70 Years
Eligibility Criteria
Inclusion Criteria:
Weight ≥15 kg;
Age ≥10 and ≤70 years;
MELD score of ≥24;
Documented liver failure;
Subject or designated representative must be willing to sign an Informed Consent Form specific to this study and comply with study requirements.
Exclusion Criteria:
Cerebral Perfusion Pressure (CPP) as measured by an intracranial pressure (ICP) monitor.:
Patients ≥ 18 yrs of age with Cerebral Perfusion Pressures ≤40 mm Hg for one hour or longer.
Patients ≤18 yrs with CPP ≤35 mm Hg for one hour or longer.
Concomitant disease including chronic congestive heart failure, vascular disease, emphysema, AIDS, cancer, acute fatty-liver disease, hepatitis due to herpes virus, Wilson's disease, or Budd-Chiari syndrome;
Portal hypertension;
Liver dysfunction due to trauma;
Hemorrhage or irreversible brain death;
Platelet count <50,000/mm3 or reducing to <80,000/mm3 over a 72 hour period;
Mean Arterial Pressures (MAP) ≤50 mm Hg for one hour or longer as measured by an indwelling arterial line, OR; patients ≤18 years old and whose MAP is ≤40 mm Hg for one hour or longer;
Vasopressor support exceeding 1.0 µg/kg/min of an alpha-adrenergic agent for one hour or longer;
Clinical or radiographic evidence of stroke or intracerebral bleeding;
Seizures uncontrolled by medication;
Acute myocardial infarction based on clinical and/or electrocardiographic evidence;
Lung disease defined by a PaO2 ≤ 60mm Hg or an FiO2 ≥0.6;
Pregnancy as determined by βhCG results;
≤2 weeks postpartum;
Eligible for an open ELAD clinical trial
12. IPD Sharing Statement
Learn more about this trial
Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
We'll reach out to this number within 24 hrs